Abbott (NYSE: ABT), an American pharmaceutical company, said that it has bagged the U.S. Food and Drug Administration's approval for its Aveir single-chamber (VR) leadless pacemaker to treat slow heart rhythms in patients. The approval has been received on the back of LEADLESS II phase 2 investigational device exemption study, which concluded that the device met its pre-specified primary endpoints. Abbott’s pacemaker doesn’t require the traditional process of an incision in the chest. The company said that its “mapping system allows to measure electrical signals within the heart and determine the correct placement of the device before final implantation.
https://www.tipranks.com/news/abbotts-leadless-pacemaker-gets-green-light?utm_source=advfn.com&utm_medium=referral
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Abbott Laboratories Charts.
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Abbott Laboratories Charts.